LAVAL, QC, May 25, 2012 /CNW/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS
Health" or the "Company") today advised that Roberto Bellini, President
and Chief Executive Officer, will present at BioFinance 2012. The
presentation will take place at 11:20 am Eastern Time on Wednesday, May
30th, 2012. The conference will be held at the St. Andrew's Club &
Conference Centre in Toronto, Ontario.
BioFinance is the leading investor conference in Canada for the life
sciences industry. This event brings together key industry players
interested in investment opportunities and issues affecting companies
in the life sciences sector. Presenting companies span a range of
industries including: biologics, medical devices, drug delivery,
vaccines, diagnostics, bio-energy, green technologies, bio materials,
industrial biotech, and research services.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a development-focused healthcare company concentrating
on products that provide innovative health solutions and address
critical unmet medical needs. The Company, in collaboration with its
partner, Celtic Therapeutics Inc., is currently advancing its novel
drug candidate KIACTA™, through a Phase III trial for the treatment of
AA amyloidosis, an orphan indication resulting in renal dysfunction
that often rapidly leads to dialysis and eventually death. AA
amyloidosis affects approximately 50,000 individuals in the United
States, Europe and Japan.
<p> Jonathan Ross<br/> TMX Equicom<br/> 416-815-0700 ext. 248 | <a href="mailto:jross@equicomgroup.com">jross@equicomgroup.com</a> </p>